Article
Acetazolamide in Acute Decompensated Heart Failure With Volume Overload
September 1, 2023
Dr. Chadwick Clinical question: Does the addition of acetazolamide to standardized loop diuretic therapy achieve more effective decongestion compared to loop diuretics alone in acute...
Article
Update in Heart Failure Care
July 5, 2023
According to the American College of Cardiology, more than 6 million Americans are living with heart failure—the leading cause of hospital admission in patients aged 65 and older. Hundreds of...
Article
There is a Decreased Risk of Hospitalization from Heart Failure in Type II Diabetics Initiated on a SGLT2 Inhibitor When Compared to a GLP-1 Receptor Agonist
- Chi Huang, MD, FACP, SFHM
September 1, 2022
Dr. Huang Clinical question: Determine the cardiovascular risk outcome in type II diabetic patients initiated on an sodium-glucose cotransporter-2 (SGLT2) inhibitor versus a glucagon-like...
Article
How to Treat Heart Failure: New Updates
- Ingrid Pinzon, MD, FACP, CHCQM-PHYADV, FHM
August 1, 2022
Case A 76-year-old man with a medical history of congestive heart failure (CHF) with left ventricular ejection fraction of 30%, hypertension, dyslipidemia, and recent hospitalization for CHF...
Article
Effective therapy for heart failure with preserved ejection fraction
- Mel L. Anderson, MD, MACP
January 7, 2022
Dr. Anderson Clinical question: What effect do sodium-glucose cotransporter 2 (SGLT2) inhibitors have on outcomes in adults with heart failure with preserved ejection fraction...
News
EHRs have no impact on inpatient heart failure clinical choices or outcomes
November 15, 2021
Relative to usual care, prognostic information at the bedside provided no advantage for heart failure care.
News
New prescription for loop diuretic improves 30-day heart failure outcomes
October 22, 2021
Does a new prescription for a loop diuretic improve short-term outcomes in patients hospitalized for heart failure?
News
Heart failure hospitalization risk lower with SGLT2 inhibitors than GLP-1 RAs
September 27, 2021
SGLT2 inhibitor versus GLP-1 RA use was associated with a significantly lower rate of hospitalization for heart failure in people with diabetes.
News
EMPEROR-Preserved: Empagliflozin’s HFpEF efficacy catalyzes a heart failure redefinition
September 20, 2021
Cardiologists have long defined heart failure as involving reduced or preserved ejection fraction. Results from big empagliflozin trials say forget that.
News
Use of point-of-care ultrasound (POCUS) for heart failure
- Adam Wachter, MD;
- Faye Farber, MD;
- Megan Brooks, MD, MPH, FHM;
- Neil Stafford, MD;
- Poonam Sharma Md, SFHM;
- Shree Menon, MD;
- Yasmin Marcantonio, MD
August 16, 2021
Hospitalist use of POCUS may include guiding procedures, aiding in diagnosis, and assessing effectiveness of treatment.